Ketorolac Baxter (Ketorolac Trometamol)

Ketorolac trometamol works by non‑selectively inhibiting the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which blocks the synthesis of prostaglandins. Reduced prostaglandin levels lower inflammation and interrupt pain signaling pathways, delivering its analgesic and anti‑inflammatory effects.

The specific dose and duration of Ketorolac Baxter are determined by the prescribing clinician based on the patient’s condition, weight, renal function, and overall risk profile. Dosing guidelines are provided in the product label and must be followed by the healthcare professional.

Safety of ketorolac during pregnancy and lactation has not been established. It is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To order Ketorolac Baxter, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials. The team then replies with pricing, availability, shipping details (including cold‑chain if needed), and required import documentation.

Ketorolac provides analgesia comparable to moderate‑dose opioids for short‑term use but carries a lower risk of respiratory depression. Compared with other NSAIDs, it has a higher potency for pain relief but also a higher risk of renal and gastrointestinal adverse effects, so its use is limited to a few days.

Ketorolac Baxter should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the vials in their original packaging until use and discard any solution that appears discolored or contains particles.

Ketorolac Baxter is administered by a healthcare professional as an intramuscular or intravenous injection. The injection is given slowly, and the dose may be repeated only if the total daily limit is not exceeded and the treatment duration remains within recommended limits.

Serious risks include gastrointestinal bleeding or ulceration, acute renal failure, severe allergic reactions such as anaphylaxis, and cardiovascular events like myocardial infarction or stroke. Patients should be monitored for signs of bleeding, changes in urine output, rash, or chest pain during therapy.

Ketorolac should be avoided in patients with known hypersensitivity to ketorolac or other NSAIDs, active gastrointestinal ulceration or bleeding, severe renal impairment, uncontrolled hypertension, and in those who are in the third trimester of pregnancy. Caution is also advised for patients on anticoagulants or with a history of cardiovascular disease.